We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY Sirona (XRAY): Q1 Strong, Expansion on Track
Read MoreHide Full Article
On Jun 17, we issued an updated research report on NY-based DENTSPLY Sirona Inc. (XRAY - Free Report) – a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products. The company currently carries a Zacks Rank #3 (Hold).
Post the recent merger with Sirona, DENTSPLY made a promising start to 2016. The company reported a better-than-expected first quarter with both earnings and revenues steering past the Zacks Consensus Estimate. Net sales increased 17.7% on a year-over-year basis to $772.6 million,
Growth at the company was primarily driven by its innovative products like WaveOne GOLD, X-Smart iQ, VDW and CONNECT Drive which are expected to expand customer base in Europe. The DENTSPLY-Sirona merger is expected to generate extensive cost savings ($125 million) by the third year of completion. A strong balance sheet and cash flow statement provide scope for further investments on product development, acquisitions and share repurchases.
DENTSPLY’s dual branding strategy, product innovation, growth opportunities in emerging markets (especially from Asia-Pacific & the Middle East/Africa), diversified product portfolio and recurring revenue base are key growth catalysts. The company provided a positive guidance, with revenue growth projected at 4% to 6% at constant currency for full-year 2016. Adjusted earnings are forecasted in the band of $2.70 to $2.80 per share.
On the flip side, apart from a series of macroeconomic headwinds, currency fluctuation continues to be the major dampener for the stock. In fact, strengthening of the U.S. dollar against Euro and other emerging market currencies impacted the company’s growth trajectory. A persistent decline in sales, accompanied by higher capital expenditure for product development kept margins under pressure.
Stocks to Consider
Better-ranked stocks in the same space include Halyard Health , CR Bard and CONMED Corporation (CNMD - Free Report) . Halyard Health sports a Zacks Rank 1 (Strong Buy) while the other two stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DENTSPLY Sirona (XRAY): Q1 Strong, Expansion on Track
On Jun 17, we issued an updated research report on NY-based DENTSPLY Sirona Inc. (XRAY - Free Report) – a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products. The company currently carries a Zacks Rank #3 (Hold).
Post the recent merger with Sirona, DENTSPLY made a promising start to 2016. The company reported a better-than-expected first quarter with both earnings and revenues steering past the Zacks Consensus Estimate. Net sales increased 17.7% on a year-over-year basis to $772.6 million,
Growth at the company was primarily driven by its innovative products like WaveOne GOLD, X-Smart iQ, VDW and CONNECT Drive which are expected to expand customer base in Europe. The DENTSPLY-Sirona merger is expected to generate extensive cost savings ($125 million) by the third year of completion. A strong balance sheet and cash flow statement provide scope for further investments on product development, acquisitions and share repurchases.
DENTSPLY’s dual branding strategy, product innovation, growth opportunities in emerging markets (especially from Asia-Pacific & the Middle East/Africa), diversified product portfolio and recurring revenue base are key growth catalysts. The company provided a positive guidance, with revenue growth projected at 4% to 6% at constant currency for full-year 2016. Adjusted earnings are forecasted in the band of $2.70 to $2.80 per share.
On the flip side, apart from a series of macroeconomic headwinds, currency fluctuation continues to be the major dampener for the stock. In fact, strengthening of the U.S. dollar against Euro and other emerging market currencies impacted the company’s growth trajectory. A persistent decline in sales, accompanied by higher capital expenditure for product development kept margins under pressure.
Stocks to Consider
Better-ranked stocks in the same space include Halyard Health , CR Bard and CONMED Corporation (CNMD - Free Report) . Halyard Health sports a Zacks Rank 1 (Strong Buy) while the other two stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>